Liu and colleagues have suggested that Gankyrin promotes tumor occurrence, metastasis and drug resistance by activating the β-catenin/c-myc signaling pathway in human hepatocellular carcinoma cell lines (26). The gene discussed is MYC; the disease is neoplasm.